RU2016134838A3 - - Google Patents

Download PDF

Info

Publication number
RU2016134838A3
RU2016134838A3 RU2016134838A RU2016134838A RU2016134838A3 RU 2016134838 A3 RU2016134838 A3 RU 2016134838A3 RU 2016134838 A RU2016134838 A RU 2016134838A RU 2016134838 A RU2016134838 A RU 2016134838A RU 2016134838 A3 RU2016134838 A3 RU 2016134838A3
Authority
RU
Russia
Application number
RU2016134838A
Other languages
Russian (ru)
Other versions
RU2016134838A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016134838A publication Critical patent/RU2016134838A/ru
Publication of RU2016134838A3 publication Critical patent/RU2016134838A3/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005Dipeptidyl-peptidase IV (3.4.14.5)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5437IL-13
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • G01N2800/122Chronic or obstructive airway disorders, e.g. asthma COPD
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/20Dermatological disorders
    • G01N2800/202Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
RU2016134838A 2014-01-27 2015-01-26 Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком RU2016134838A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461931878P 2014-01-27 2014-01-27
US61/931,878 2014-01-27
US201461990932P 2014-05-09 2014-05-09
US61/990,932 2014-05-09
PCT/US2015/012885 WO2015112970A1 (en) 2014-01-27 2015-01-26 Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung

Publications (2)

Publication Number Publication Date
RU2016134838A RU2016134838A (ru) 2018-03-07
RU2016134838A3 true RU2016134838A3 (cg-RX-API-DMAC7.html) 2018-09-27

Family

ID=53682019

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016134838A RU2016134838A (ru) 2014-01-27 2015-01-26 Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком

Country Status (12)

Country Link
US (1) US20160363591A1 (cg-RX-API-DMAC7.html)
EP (2) EP3099323A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017509692A (cg-RX-API-DMAC7.html)
KR (1) KR20160113700A (cg-RX-API-DMAC7.html)
CN (1) CN105934254A (cg-RX-API-DMAC7.html)
AU (1) AU2015209124A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016017192A2 (cg-RX-API-DMAC7.html)
CA (1) CA2937387A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016009491A (cg-RX-API-DMAC7.html)
RU (1) RU2016134838A (cg-RX-API-DMAC7.html)
SG (1) SG11201606102UA (cg-RX-API-DMAC7.html)
WO (1) WO2015112970A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862762B2 (en) 2014-02-07 2018-01-09 Medimmune, Llc Monoclonal antibodies which bind human periostin
EP3242686B1 (en) 2015-01-09 2020-07-08 Medimmune, LLC Assay to detect human dpp-4
JP2018538249A (ja) * 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−4およびペリオスチン
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
IL265473B2 (en) * 2016-09-23 2024-01-01 Genentech Inc Uses of il-13 antagonists for treating atopic dermatitis
US10386368B2 (en) 2017-02-24 2019-08-20 Trustees Of Boston University Isolation of human lung progenitors derived from pluripotent stem cells
CN109055522A (zh) * 2018-07-03 2018-12-21 吉林大学 C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用
WO2020096381A1 (ko) 2018-11-09 2020-05-14 아주대학교 산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN113155996A (zh) * 2021-03-23 2021-07-23 广州医科大学附属第一医院(广州呼吸中心) 15(s)-羟基二十碳四烯酸在评估变应原特异性免疫治疗效果中的应用
PE20251639A1 (es) 2022-06-17 2025-06-24 Apogee Biologics Inc Anticuerpos que se unen a interleuquina 13 y metodos de uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP1631680A2 (en) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP4980878B2 (ja) * 2004-02-23 2012-07-18 エラスムス ユニバーシティ メディカル センター ロッテルダム 遺伝子発現プロファイリングによる急性骨髄性白血病の分類、診断、および予後
WO2008073463A2 (en) * 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
US20090155784A1 (en) * 2007-01-22 2009-06-18 Wyeth Assessment of asthma and allergen-dependent gene expression
WO2008097198A1 (en) * 2007-02-09 2008-08-14 Agency For Science, Technology And Research Apparatus and method for analysis of data traffic
DK2644713T3 (en) * 2007-10-23 2018-08-20 Clinical Genomics Pty Ltd A Method for Diagnosing Neoplasms II
MX348362B (es) 2008-03-31 2017-06-07 Genentech Inc * Composiciones y metodos para tratar y diagnosticar asma.
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20130281876A1 (en) * 2010-10-15 2013-10-24 Medimmune Limited Therapies for improving pulmonary function
TWI666447B (zh) 2010-12-16 2019-07-21 建南德克公司 關於th2抑制作用之診斷及治療
WO2012158954A1 (en) 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders

Also Published As

Publication number Publication date
CN105934254A (zh) 2016-09-07
MX2016009491A (es) 2017-01-13
EP3099323A4 (en) 2017-10-04
JP2017509692A (ja) 2017-04-06
WO2015112970A1 (en) 2015-07-30
RU2016134838A (ru) 2018-03-07
EP3685857A1 (en) 2020-07-29
BR112016017192A2 (pt) 2017-10-10
US20160363591A1 (en) 2016-12-15
CA2937387A1 (en) 2015-07-30
SG11201606102UA (en) 2016-08-30
AU2015209124A1 (en) 2016-08-18
EP3099323A1 (en) 2016-12-07
KR20160113700A (ko) 2016-09-30

Similar Documents

Publication Publication Date Title
BR112016018076A2 (cg-RX-API-DMAC7.html)
BR112016016195A2 (cg-RX-API-DMAC7.html)
BR112016015813A2 (cg-RX-API-DMAC7.html)
BR112016016951A2 (cg-RX-API-DMAC7.html)
BR112016018238A2 (cg-RX-API-DMAC7.html)
BR112016017303A2 (cg-RX-API-DMAC7.html)
BR112016016088A2 (cg-RX-API-DMAC7.html)
BR112016015605A2 (cg-RX-API-DMAC7.html)
BR112016016094A2 (cg-RX-API-DMAC7.html)
BR112016016741A2 (cg-RX-API-DMAC7.html)
BR112016018369A2 (cg-RX-API-DMAC7.html)
BR112016017657A2 (cg-RX-API-DMAC7.html)
BR112016016451A2 (cg-RX-API-DMAC7.html)
BR112016017137A2 (cg-RX-API-DMAC7.html)
BR112016016751A2 (cg-RX-API-DMAC7.html)
BR112016018575A2 (cg-RX-API-DMAC7.html)
BR112016018705A2 (cg-RX-API-DMAC7.html)
BR112016015779A2 (cg-RX-API-DMAC7.html)
BR112016016992A2 (cg-RX-API-DMAC7.html)
BR112016016268A2 (cg-RX-API-DMAC7.html)
BR112016016944A2 (cg-RX-API-DMAC7.html)
BR112016015768A2 (cg-RX-API-DMAC7.html)
RU2016134838A3 (cg-RX-API-DMAC7.html)
BR112016017216A2 (cg-RX-API-DMAC7.html)
BR112016016537A2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190212